Phase 2 Muscle Invasive Bladder Cancer Clinical Trials
24 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 24 trials
Recruiting
Phase 1Phase 2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 2
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
Muscle Invasive Bladder Cancer (MIBC)
Peking University Third Hospital58 enrolled1 locationNCT07647289
Recruiting
Phase 2
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Muscle Invasive Bladder Cancer
Astellas Pharma Global Development, Inc.240 enrolled9 locationsNCT07475806
Recruiting
Phase 2
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
Non Muscle Invasive Bladder Cancer
BLATAM37 enrolled1 locationNCT06972615
Recruiting
Phase 1Phase 2
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled20 locationsNCT05710848
Recruiting
Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
Protara Therapeutics131 enrolled66 locationsNCT05951179
Recruiting
Phase 2
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Non Muscle Invasive Bladder Cancer
White River Junction Veterans Affairs Medical Center240 enrolled9 locationsNCT05796375
Recruiting
Phase 2
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Urothelial CarcinomaMuscle Invasive Bladder Cancer
University of California, Irvine23 enrolled1 locationNCT06682728
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 2
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled14 locationsNCT07283835
Recruiting
Phase 2
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
High-risk Non-muscle Invasive Bladder Cancer
CG Oncology, Inc.325 enrolled65 locationsNCT06567743
Recruiting
Phase 2
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Non Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
John Sfakianos60 enrolled4 locationsNCT06503614
Recruiting
Phase 2
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
CHU de Quebec-Universite Laval160 enrolled7 locationsNCT05327647
Recruiting
Phase 2
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
Muscle Invasive Bladder Cancer
Spanish Oncology Genito-Urinary Group90 enrolled23 locationsNCT06511648
Recruiting
Phase 2
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital25 enrolled12 locationsNCT07296705
Recruiting
Phase 2
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc.90 enrolled16 locationsNCT03945162
Recruiting
Phase 1Phase 2
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Triple Negative Breast Cancer(TNBC)Colorectal Cancer (CRC)+6 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 1Phase 2
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Phase 2
Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC
Non Muscle Invasive Bladder Cancer
Relmada Therapeutics, Inc.70 enrolled1 locationNCT06663137
Recruiting
Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Non Muscle Invasive Bladder Cancer
Robert Svatek166 enrolled2 locationsNCT04375813